SLC16A1 and pancreatic neoplasm: Our data suggests that the combination of irinotecan, or liposomal irinotecan as described in the NAPOLI-3 trial (Wang-Gillam et al., 2019; Wainberg et al., 2023), with ME3BP-7 could improve the potency as well as address the pockets of heterogeneity with low MCT1 in pancreatic cancer (Figure 4, Figure 4—figure supplement 1).